Actively Recruiting
Phase 2 Study of Epcoritamab for Adults With Previously Treated Waldenstrom Macroglobulinemia
Led by Gottfried von Keudell, MD PhD · Updated on 2026-03-13
20
Participants Needed
3
Research Sites
35 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating epcoritamab, a bispecific antibody that activates the immune system to target cancer cells, in people with previously treated Waldenstrom Macroglobulinemia WM, a type of B-cell lymphoproliferative disorder. This prospective Phase 2 trial aims to determine if epcoritamab can be used to treat WM patients who have had prior therapies including anti-CD20 antibodies and BTK inhibitors. The study is funded by Genmab, Inc. and includes about 20 participants. Participants will receive epcoritamab through subcutaneous injections following a structured dosing schedule over up to 12 cycles each cycle is 28 days. The treatment starts with more frequent dosing in cycles 1 to 3, then less frequent dosing in cycles 4 to 9, and finally monthly dosing in cycles 10 to 12. Study procedures include baseline and follow-up CT scans and bone marrow biopsies. The trial includes a safety lead-in dose escalation phase to find the recommended dose, followed by a phase 2 treatment period. After treatment, participants will have follow-up visits every 3 months for 2 years. During the study, participants undergo various assessments such as blood tests, electrocardiograms, bone marrow biopsies, and questionnaires to monitor health and response. Researchers will measure overall response rate after up to 12 treatment cycles as the primary outcome, along with other outcomes like progression-free survival and toxicity rates. The total participation can last over two years including treatment and follow-up. Safety and treatment effects will be carefully monitored throughout the trial.
CONDITIONS
Brief Title
Epcoritamab in Previously Treated WM
Research Team
G
Gottfried von Keudell, MD, PhD
D
Dea hunsicker, MSN
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here